BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to SGN-35 for the treatment of Hodgkin lymphoma. SGN-35, an antibody-drug conjugate (ADC), is in an ongoing pivotal trial under a Special Protocol Assessment (SPA) from the FDA for relapsed or refractory Hodgkin lymphoma.
